by Marios Dimopoulos
Hemp oil is a concentrated form of cannabis that is consumed orally. Consuming large amounts of oil for a period of three to six months, almost every disease you can imagine can be cured or completely controlled. This is possible because cannabis acts through the endocannabinoid system, the hyperregulatory system of our body, which maintains homeostasis in other systems.
You can see the effectiveness of medicinal cannabis in all diseases in which smoking cannabis is beneficial. It is known that people with cancer, chronic pain, inflammatory conditions and other diseases that smoke cannabis have remarkable effectiveness. It is quite strange that putting cannabis on fire and inhaling the smoke (which results in you taking the cannavoids in the form of a low concentration through the lungs) works better than many expensive drugs.
With hemp oil, however, there are two main differences: First, cannabinoids are much more concentrated than with tobacco, and so it has a more powerful effect on our systems. Secondly, we consume the oil, we do not smoke it, which means that it is digested through the system that needs to absorb the ingredients. In essence, we feed our body with molecules that allow us to stay in balance, and since all diseases are of some kind of imbalance, this drug is effective against almost any ailment.
Banning medicinal cannabis is a crime against humanity
There are hundreds of scientific studies that show that cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) are effective against almost any disease. Some of the diseases that science has proven that cannabinoids can cure are arthritis, cancer, Crohn’s disease, diabetes, fibromyalgia, multiple sclerosis and Parkinson’s disease.
The American College of Physicians (ACP) issued a statement in 2008 approving the medical use of marijuana. The group is pressuring the U.S. government to undo the ban on marijuana treatments. The American College of Physicians encourages the use of non-smoking forms of THC (the main psychoactive ingredient of marijuana) that have been shown to have therapeutic value. The American College of Physicians, which is the second largest physicians’ organization in the U.S., reported studies on the medical applications of marijuana, such as treating severe weight loss associated with diseases such as AIDS and treating nausea and vomiting caused by chemotherapy in cancer patients (1).
Medical cannabis has antiarctic effects, which are responsible for preventing or delaying the development of cancer. This means that cannabinoids offer cancer patients a treatment option in the treatment of aggressive cancers.
Science argues that hashish oil containing high amounts of THC should be a primary treatment of cancer and not just have a supportive role in controlling the side effects of chemotherapy.
Hemp oil has long been recognized as one of the most beneficial ingredients known to humans. Derived from the seeds of cannabis, it has been characterized as a superfood due to its high content of essential fatty acids and its unique ratio of omega-3 to omega-6 and gamma linolenic acid (GLA) – 2:5:1. Hemp oil contains over 5% pure GLA, a much higher concentration than any other plant, higher even than spirulina. For thousands of years the cannabis plant has been used in elixirs and medicinal teas due to its healing properties.
Both the legal commercial form of hemp oil and the illegal hemp oil rich in THC are one of the most powerful protein sources present in the plant kingdom.
Rick Simpson, a canadian individual, makes hemp oil and distributes it to friends and acquaintances, without charging it. In small doses, he says, he does you well without raising you. “You can’t refuse your eyes,” the Simpson says. “Here someone is to die of cancer and eventually does not die. I do not care if the remedy comes from the tomato plant, the potato plant or the cannabis plant. If the drug is safe, it helps and has effectiveness, why not use it?” he asks.
When a person has cancer and dies, this question is very important. The bravery of Rick Simpson in showing us with videos on the internet how to make hemp oil ourselves offers many people hope to be appreciated as money is spent on expensive cancer treatments. We need cheap medicines in the future, and there is nothing better than what we can make ourselves cheaply.
According to Dr. Robert Ramer and Dr. Burkhard Hinz of the University of Rostock in Germany, medicinal cannabis can be an effective treatment of cancer (2). Their research was published in the Journal of the National Cancer Institute Advance Access on December 25, 2007 in a study titled “Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1”. From this research, scientists learned that treatment with cannabinoids, one of the active ingredients of medicinal cannabis, has been shown to reduce the infiltration of cancer cells, i.e. their ability to infiltrate and actively destroy environmental tissues.
It is already known that cannabis can increase patients’ appetite, but researchers have learned that cannabinoids, in addition to having relieving benefits in the treatment of cancer, have anticancer effects, which are responsible for preventing or delaying the development of cancer.
Marijuana reduces the growth of malignant lung tumor in half, shows a 2007 study by Harvard Medical School. The active ingredient in marijuana reduces tumor growth in lung cancer in half and significantly reduces the cancer’s ability to spread, say researchers at Harvard University who examined the ingredient in laboratory and mouse studies. “The beauty of this study is that we show that an abuse component, if used wisely, can provide a new path in the treatment of lung cancer,” said Anju Preet, Ph.D., a researcher in the department of Experimental Medicine.
Targeting the CB1 and CB2 canabinoid receptors, endocannabinoids (which are cannabinoids that are naturally produced in the body and activate these receptors) as well as the THC of marijuana are considered to play a role in a variety of biological functions, including the control of pain and anxiety and inflammation.
Researchers reported in the August 2004 issue of Cancer Research, the journal of the American Association for Cancer Research, that cannabis ingredients prevented the spread of brain cancer in biopsies of human tumors (3). A research team from the University of South Florida noted that THC can selectively prevent the activation and replication of herpes viruses. Viruses, which can be in a latent state for years within white blood cells before they become active and spread to other cells, are thought to increase one’s chances of developing cancers such as Kaposi sarcoma, Burkitt’s lymphoma and Hodgkin’s disease.
In 1988, a research team at the Complutense University of Madrid discovered that THC can bring about selectively programmed cell death in brain tumor cells, without negatively affecting adjacent healthy cells. In 2000 they reported in the journal Nature Medicine that injections of synthetic THC eliminated malignant gliomas (brain tumors) in one-third of the cured rats and prolonged life to the other third of the rats six weeks. Led by Dr. Manuel Guzman, the Spanish team announced that it had destroyed incurable cancerous tumors in rats by injecting them with THC (4).
Researchers at the University of Milan reported in the Journal of Pharmacology and Experimental Therapeutics that the non-psychotropic components in cannabis prevented the growth of glial-causing glial cells and selectively targeted and killed cancer cells through the process of apoptosis. “Non-psychoactive CBD causes a significant anti-oncic effect in both cell culture and living organisms, thus suggesting a possible application of CBD as an anticancer agent” (5).
The first experiment to document the anti-oncic effects of cannabis was conducted in 1974 at Virginia Medical College. The results of this study were that the psychoactive component of cannabis THC “delayed the development of lung, breast and viral leukaemia cancers in laboratory mice and prolonged their lives by 36%” (6). Funded by the National Institute of Health to find evidence that cannabis destroys the immune system, the study found instead that THC delayed the development of three types of cancer in mice. The DEA (Drug Enforcement Administration) quickly halted the study.
A 1975 article in the Journal of the National Cancer Institute entitled “Antineoplastic Activity of Cannabinoids” (Anticancer Activity of Cannabinoids) stated: “The development of Lewis lung adenocarcinoma was slowed down by oral administration of tetrahydrocannabinol (THC) and cannabinol (CBN)” – two types of cannabinoids, a family of active cannabis components. “In mice treated for 20 consecutive days with THC and CBN, the size of their primary tumor was reduced.”
It is legal for doctors to give people their chemical poisons, but you can go to jail if you try to save yourself or a loved one from cancer with hemp oil.
There are hundreds of scientific studies that show that cannabis is effective against cancer. There is therefore absolutely no reason why medicinal cannabis should not be legalised and hemp oil should not be given to cancer patients. Unfortunately we live in a world in which governments and doctors prefer to see people die than to have access to this safe and effective anticancer drug.
In 2006 scientists in England revealed that cannabis has the potential to destroy leukaemia cells. Dr Wai Man Liu and his team at Queen Mary’s School of Medicine and Dentistry in London found that the main active ingredient in cannabis, tetrahydrocannabinol (THC), can be used effectively against some cancers.
Although there has been scientific evidence that cannabis can shrink or even kill tumors since the 70’s, the recent strong interest in this research has been sparked by Run From The Cure, a documentary about a Canadian who claims that the oil from the cannabis plant cured his skin cancer. He then tried the treatment on many other cancer patients in his community with similar results.
The video has motivated hundreds of other people to try this treatment on themselves. It is therefore worth looking at these allegations and the investigations that support them. Today there are dozens of videos on YouTube of people who have tried the same treatment. Many claim that hemp oil has cured their cancers, and some of these videos include day-to-day photos showing their tumors shrinking. Despite the fact that there are no official clinical trials supporting these claims, the idea that cannabis has strong anticancer properties is supported by preclinical, laboratory and animal studies.
Dr. Robert Melamede states: “Over 600 scientific articles show that many cancers (lung, breast, prostate, glioma, thyroid, leukemia, lymphoma, basal cell carcinoma, melanoma, etc.) are killed by cannabinoids in tissue culture and animal studies.” The idea that cannabis can cure cancer is also supported by epidemiological studies, which have found that long-term marijuana users have significantly lower rates of certain cancers than non-users.
See below how and why cannabis cures cancer, according to scientific explanations
Gliomas, a very aggressive form of brain cancer, even with successful surgery, radiation and chemotherapy, takes the lives of 75% of its victims within 2 years and literally takes everyone’s life within 5 years. But if there was an alternative treatment for gliomas, that could selectively target the cancer leaving healthy cells intact? And yet there is probably such a cure.
In 2008, a book entitled “Emerging Clinical Applications for Cannabis and Cannabinoids: A Review of the Scientific Literature” was published, which lists over 150 preclinical and clinical studies evaluating the therapeutic properties of cannabis and its various active ingredients, known as cannabinoids. One chapter of the book includes in summary the findings of more than 30 trials on the use of cannabinoids as anticancer agents, particularly for the treatment of gliomas.
Over the past 10 years scientists from all over the world have found that cannabinoids can stop the spread of many cancer cells, including prostate, breast (7), lung (8), pancreatic cancer (9) and brain cancer (10). In January 2008, a study entitled “Cannabinoids for Cancer Treatment: Progress and Promise” was written in the journal, which presents many studies on the anticancer activity of cannabinoids (11). A trial published in 2006 in the British Journal of Cancer reported that intracranial THC administration was linked to reduced proliferation of cancer cells in people with advanced glioblastoma (12).
In 2008 in the scientific journal Expert Review of Neurotherapeutics Italian researchers reported that “cannabinoids have demonstrated a strong ability to reduce the growth of glioma tumors. They are selective anti-oncic agents, as they kill glioma cells without affecting healthy cells” (13).
The ban on cannabis has no scientific basis. To date there are over 20,000 published studies or journals in the scientific literature evaluating cannabis and its cannabinoids, and almost a third of them have been published in the last three years. The scientific findings of the majority of modern research contradict the position of most states that cannabis is a particularly dangerous ingredient worthy of prohibition.
For example, in February 2010 researchers at the University of California Center for Medicinal Cannabis Research announced the findings of a series of randomized, placebo-controlled clinical trials on the therapeutic usefulness of inhaled cannabis. The studies concluded that marijuana should be the first line of treatment for patients with neuropathy and other serious diseases. Among these studies conducted by the Center, four evaluated the ability of marijuana, when smoked, to relieve the pain of neuropathy, a difficult to treat type of nerve pain associated with cancer, diabetes, AIDS and other diseases. All trials found that cannabis reduced patients’ pain to an extent that was better than the available medications.
Another study conducted by the Center’s researchers evaluated the use of marijuana as a treatment for patients suffering from multiple sclerosis. This study found that “cannabis smoked was superior to placebo in reducing spasticity and pain in patients with multiple sclerosis and provided some benefits beyond prescribed medications.”
A 2010 review by researchers in Germany reports that since 2005 there have been 37 controlled studies that evaluated the safety and efficacy of marijuana and the ingredients it contains in 2563 people.
While researchers in the 1970s, 80s and 90s initially evaluated the ability of cannabis to temporarily relieve the various symptoms of diseases – such as the nausea associated with chemotherapy – scientists are examining the role of cannabinoids in the treatment of diseases.
Specifically, scientists examine the ability of cannabinoids to treat autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and inflammatory bowel diseases, as well as their role in the treatment of neurological diseases such as Alzheimer’s disease and Lou Gehrig’s disease. Researchers are also studying the anticancer properties of cannabis, as a growing body of preclinical and clinical studies concludes that cannabinoids may reduce the spread of cancer cells through apoptosis (programmed cell death) and through the inhibition of angiogenesis (the formation of new blood vessels).
The discovery of an endogenous cannabinoid system with specific receptors has advanced our understanding of the therapeutic effects of folklore cannabis into a reliable science. Now it is becoming obvious that the cannabinoid system evolved with our species and was included in normal human physiology, especially in the control of movement, pain, reproduction, memory and appetite, among other biological functions. In addition, the presence of cannabinoid receptors in the brain and peripheral tissues indicates that the cannabinoid system forms a previously unknown universal network of the nervous system.
Fans of the therapeutic use of cannabis and cannabinoids say patients should not smoke their medicine. Patients who wish to quickly initiate the action associated with inhalation, but are concerned about the possible damage of the smoke, eliminate the intake of carcinogenic components by vaporizing cannabis rather than smoking it. The vaporization of cannabis limits respiratory toxins by heating cannabis to a temperature capable of forming vapors (around 180-190 degrees Celsius), but below the burning point (around 230 degrees Celsius), where harmful smoke and related toxins (such as carcinogenic hydrocarbons) are produced.
This procedure removes the health risks of smoking. In clinical trials vaporization has been shown to safely and effectively deliver the pharmacologically active cannabinoids deep into the lungs, where the vessel-rich tissue will carry them to the tissues of the whole body.
Most large medical groups, including the Institute of Medicine, agree that cannabis is an ingredient with significant therapeutic value whose “side effects are within the context of the effects tolerated for other drugs.” A decade ago the Drug Enforcement Administration (DEA) studied the healing properties of cannabis. After an in-depth study, government judge Francis L. Young concluded: “The evidence clearly shows that marijuana is capable of relieving the strain of a large number of very sick people, and it does this safely under medical supervision.”
This herb and its healing components affect every aspect of our body and our mind. Let’s see how such universal action has. American doctors of Integrative Medicine, who in their clinics treat thousands of patients with a multitude of diseases and symptoms, assure that almost all their patients have benefit from the use of cannabis. But how can an herb help in so many different ailments? How can it have both a comforting and a therapeutic effect? How can it be so safe when it has such a powerful effect? Research to answer these questions led scientists to discover a previously unknown physiological system, necessary for the health and treatment of every human and almost every animal, the endocannabinoid system.
The internal cannabinoid system, so named after the plant that led to its discovery, is perhaps the most important physiological system involved in maintaining human health. Endocannabinoids and their receptors are found throughout the body: in the brain, organs, connective tissues, glands and immune cells. In each tissue the cannabinoid system performs a different task, but the goal is always the same: homeostasis, maintaining a stable internal environment despite changes in the external environment.
Cannabinoids cause homeostasis at every level of life. Let’s look at an example: autophagy, the process in which a cell makes a part of its contents self-eaten and recycled, is regulated by the cannabinoid system. While this process keeps normal cells alive, allowing them to maintain a balance between synthesis, degradation and subsequent recycling of cellular products, it has a lethal effect on malignant tumor cells, making them consume themselves with planned cellular suicide. The death of cancer cells causes homeostasis and survival throughout the body.
Endocannabinoids and cannabinoids are also found at the intersection of different body systems, allowing communication and coordination between different types of cells. For example, cannabinoids can be found at the site of an injury, reducing the release of activators and sensitizers from the injured tissue, stabilizing nerve cells to prevent excessive inflammation and calming neighboring immune cells to prevent the release of inflammatory components. Three different mechanisms of action in three different types of cells for a single purpose: to minimize the pain and damage caused by the injury.
The endocannabinoid system with its complex actions on our immune system, our nervous system and all the organs of our body is literally a bridge between the body and the mind.
Cannabinoid receptors are present throughout the body, rooted in cell membranes, and are believed to be more than any other receptor system. When the receptors of cannabinoids are stimulated, a variety of physiological processes follow. Researchers have distinguished two cannabinoid receptors: CB1, which is found mainly in the nervous system, connective tissues, genital glands, glands and organs, and CB2, which is mainly found in the immune system. Many tissues contain both receptors, and each binds to a different action. Researchers hypothesize that there is a third cannabinoid receptor.
Endocannabinoids are components that our body produces naturally, to stimulate these receptors. The most well understood of these molecules are called anandamide and 2-arachidonoylglycerol (2-AG).
Phytocannabinoids are components of plants that stimulate cannabinoid receptors. Delta-9-tetrahydrocannabinol or THC is the most psychoactive and the most popular of these ingredients, but other cannabinoids such as cannabidiol (CBD) and cannabinol (CBN) are gaining the interest of researchers due to their diverse therapeutic properties. Most phytocannabinoids have been isolated from cannabis sativa, but other healing herbs, such as echinacea purpura, have been found to contain non-psychotropic cannabinoids.
The marijuana plant also uses THC and other cannabinoids to promote its own health and prevent diseases. Cannabinoids have antioxidant properties that protect the leaves from ultraviolet radiation. Cannabinoids neutralize harmful free radicals created by UV rays, protecting cells. In humans, free radicals cause aging, cancer and other diseases.
Laboratories can also produce cannabinoids. The synthetic THC, marketed as dronabinol (Marinol) and nabilone (Cesamet), an analogue of THC, are both approved drugs by the FDA for the treatment of severe nausea. Other doctors have found them useful in the treatment of chronic pain, migraine and other serious diseases. Many other synthetic cannabinoids are used in animal research and some have a power 600 times greater than the power of THC.
As researchers study cannabis and cannabinoids, they realize that a functioning cannabinoid system is essential for health. From implanting the embryo in the wall of our mother’s uterus, to breastfeeding and growth, to responding to injuries, endocannabinoids help us survive in a rapidly changing and hostile environment. Realizing this, scientists have begun to wonder: Can a person strengthen his cannabinoid system by taking complementary cannabis? Beyond the treatment of symptoms, beyond even the treatment of diseases, can cannabis help us prevent diseases and promote our health by stimulating the ancient cannabinoid system?
Many scientists now believe that the answer is yes. Research shows that small doses of cannabinoids from marijuana can signal the body to produce more endocannabinoids and to manufacture more cannabinoid receptors. That is why many people who smoke marijuana for the first time do not feel any effect, but in the second or third time they smoke the plant they have prepared more cannabinoid receptors and are ready to respond. More receptors increase a person’s sensitivity to cannabinoids, smaller doses have greater effects, and the person has increased activity of endocannabinoids. Small, regular doses of marijuana can act as a tonic in our central physiological healing system.
Many doctors react negatively to the thought of administering a herbal ingredient and do not like the idea of smoking one’s medicine. Our medical system Our medical system is familiar with unique, isolated ingredients that can be administered oral or injectable. Unfortunately this model significantly limits the therapeutic capacity of cannabinoids.
Unlike synthetic derivatives, cannabis contains hundreds of different cannabinoids, including THC, which all act synergistically to cause better medical results and fewer side effects than THC alone. While marijuana is safe and works well, when we smoke it, many patients prefer to use a vaporizer formulation or tincture of cannabis. Scientific research and patient testimonials show that marijuana has a greater therapeutic effect than synthetic cannabinoids.
So is it possible for medicinal cannabis to be the most powerful medicine for the treatment of all human diseases, an ingredient that prevents diseases, and a plant that protects us in the ever-increasing toxic and carcinogenic environment we live in? The answer is yes. This was well known in the traditional medical systems of ancient India, China and Tibet, and is beginning to become quite well known by Western science as well. Of course we need more research on people who study the effectiveness of cannabis, but the evidence is already many and is getting bigger and bigger.
Cannabis can be an effective anti-cancer drug. Studies show that it may be effective in the treatment of gliomas (brain tumors). In September 1998 in the journal FEBS Letters researchers from the Faculty of Biology of the University of Madrid first reported that delta-9-THC caused apoptosis (programmed cell death) in glioma cells in culture (14). The researchers continued their initial findings in 2000 and reported that the administration of THC and synthetic cannabinoids WIN 55,212-2, caused significant regression of malignant gliomas in animals (15). The researchers reaffirmed the ability of cannabinoids to prevent tumor growth in animals in 2003 (16).
In the same year Italian researchers from the Department of Pharmacology, Chemotherapy and Toxicology of the University of Milan reported that the non-psychotropic cannabinoid, cannabidiol (CBD), prevented the growth of various human cells of gliomas in culture and in vivo. Writing in the November 2003 issue of the Journal of Pharmacology and Experimental Therapeutics Fast Forward, the researchers concluded: “Non-psychoactive CBD causes significant anti-oncic effects in vitro and in vivo, thus suggesting a possible application of CBD as an anticancer agent (17).
In 2004, Guzman and colleagues reported that cannabinoids prevented the development of gliomas tumors in animals and in human samples of glioblastoma (CBM) by changing the morphology of blood vessels. Writing in the August 2004 issue of the journal Cancer Research, the researchers concluded that “the current laboratory and clinical findings provide an original pharmacological target for cannabis-based therapies” (18).
Researchers at the California Pacific Medical Center Research Institute reported that the administration of THC to culture of human glioblastoma cells reduced the spread of cancer cells and caused cell death more quickly than administration of WIN 55,212-2. The researchers also pointed out that THC selectively targeted cancer cells, leaving healthy cells unaffected in a better way than the synthetic cannabinoid (19). A preclinical trial reported that the combination of THC and a medicinal drug, temozolomide (TMZ), enhanced autophagy (programmed cell death) in brain tumors resistant to conventional anticancer therapies (20).
Researchers have also reported that THC administration reduces the growth of glioblastoma tumors in patients diagnosed with recurrent GBM (glioblastoma multiforme). In the first pilot clinical trial done to assess the use of cannabinoids against GBM, the researchers found that intra-volume THC administration was associated with reduced spread of cancer cells in two of the 9 patients. “The good safe profile of THC, along with its potential action against the spread of cancer cells noted here and in other studies, may lay the basis for future trials aimed at evaluating the anti-oncic effect of cannabinoids,” the researchers concluded (21). Other researchers have also recently done additional exploration of cannabis-based therapies for the treatment of glioblastoma (22-24).
A separate report published in 2011 in the Journal of the International Society for Pediatric Neurosurgery also documents the sudden regression of brain tumors in two children treated with cannabis (25).
Alongside the ability of cannabinoids to mitigate glioma cells, other studies show that cannabinoids and endocannabinoids can also inhibit the spread of other cancer cells, such as breast, prostate, rectal, rectal bowel, gastric adenocarcinoma, skin carcinoma, leukemia cells, neuroblastoma, lung carcinoma, uterine, thyroid epithelioma, pancreatic adenocarcinoma, cervical carcinoma, oral cancer and lymphoma;
A Harvard study published on April 17, 2007 shows that the active ingredient in marijuana, THC, reduces the growth of tumors in lung cancer in half and significantly reduces the cancer’s ability to spread. Harvard researchers looked at THC in laboratory studies and in studies in mice. The researchers said that THC acts naturally by producing receptors to fight lung cancer (26). In a British pilot study researchers injected THC for three weeks in mice, in which human lung cancer cells were transplanted and found that tumors decreased in size and weight by about 50% in treated mice compared to the control group. There was also a 60% reduction in cancerous lesions in the lungs of these mice as well as a significant decrease in the markers of proteins associated with cancer progression.
According to a 2007 study and a 2010 study at the California Pacific Medical Center For Research Institute, cannabidiol (CBD) stops breast cancer from spreading throughout the body by regulating a gene called ID1. This can be a non-toxic alternative treatment to chemotherapy, achieving the same results without the painful and unwanted side effects of chemotherapy. The research team says that CBD acts by blocking the action of a gene called ID1, believed to be responsible for metastasis (27).
Consequently, many experts now believe that cannabinoids “are a new class of anticancer drugs that delay the development of cancer, prevent angiogenesis and metastasis of cancer cells” (28-29).
Cannabis can prevent cancer as well as many other diseases, and is a promising drug for the treatment of cancer. So why does the authoritarian establishment ban the use of cannabis for medical purposes, with the result that patients cannot find such an effective remedy for the treatment of their various ailments?
35 scientific studies proving that cannabis can be the medicine for cancer
Below I list 35 scientific studies that have been published in official medical journals and prove that cannabis can cure cancer. These studies are being concealed from the pharmaceutical companies because, if medicinal cannabis is allowed in all states, this will be the definitive end of the pharmaceutical companies and the large profitable company called chemotherapy. Let’s look at all the studies categorized by condition.
A. Brain cancer
1. In 2006, a study was published in the British Journal of Cancer, where tetrahydrocannabinol was administered to patients with gliblastoma (brain cancer) with very good results. The authors of the study reported that so far there had been many animal studies that showed that tetrahydrocannabinol other canavoids prevent tumor growth and angiogenesis. But there had been no study in humans. So these scientists did a pilot trial, in which they administered to 9 patients with glioblastoma tetrahydrocannabinol intracranially into the tumor. Patients had not seen any benefit from conventional treatments (surgery and radiation) and had clear evidence of tumor progression. Tetrahydrocannabinol prevented the proliferation of cancer cells in culture and reduced the cell of ki67 tumors when administered to two patients (30).
2. In 2001, a study was published in the journal Cancer Research, which showed that the selective activation of CB(2) cannabinoid receptors in the brain in mice prevented the development of glioma (31).
3. In 2003, a study entitled “The anti-oncic effect of cannavodiol, a non-psychotropic cannabinoid in human glioma cells,” was published in the journal Pharmacology and Experimental Therapeutics. The researchers of the study wrote: “Recently cannabinoids (CBs) have been shown to have anti-oncic properties. We did this study to evaluate in vitro (in test tubes) the ability against proliferation of cannabidiol (CBD), a non-psychotropic cannabinoid component, in human human cells of human glioma U87 and U373.
Eventually, cannabidiol was administered to mice and significantly inhibited the growth of human U87 glioma cells that were implanted subcutaneously in mice. In conclusion, the non-psychotropic cannabidiol (CBD) was capable of causing significant antivolemic activity both in vitro (laboratory) and in vivo (in living organisms), thus suggesting a possible application of cannabidiol as an antineoplastic (anticancer) agent” (32).
4. In 2011, a study entitled “A combination preclinical treatment of cannabinoids and temezolomide against glioma” was published in the journal Molecular Cancer Therapeutics. The authors of the study write: “Glioblastoma multiforme is very resistant to today’s anticancer therapies, and so it is imperative to find new therapeutic strategies that will help improve the poor prognosis of patients suffering from the disease. Δ9-Tetrahydrocannabidiol (THC), the important active ingredient in marijuana, and other cannabinoid receptor agonists prevent tumor growth in animal cancer models, including glioma, an effect based, at least in part, on stimulating apoptosis (cell death) through autophagy of cancer cells.
Here we show that the combined administration of tetrahydrocannabidiol (THC) and temozolomide has a strong antianginal effect on gliomas xenomyses, an effect that is also observed in tumors that are resistant to treatment with temezolomide. The combined administration of tetrahydrocannabidiol and temozolomide enhanced autophagy. The administration of tetrahydrocannabidiol and cannabidiol (CBD) (another cannabinoid that also causes cell death of gliomas through a mechanism of action different from that of tetrahydrocannabidiol) significantly reduces the development of glioma xenomografts.
In addition, treatment with temezolomide and tetrahydrocannabidiol and cannabidiol caused a strong antiogic effect both in temozolomide-sensitive and in temozolomide-resistant tumors. Our findings support that the combined administration of tetrahydrocannabidiol and cannabinoids can be used therapeutically for the treatment of glioblastoma multiforme” (33).
5. In 2007, a study entitled “Cannabinoids and gliomas” was published in the journal Molecular Neurobiology. The authors of the study write: “Cannabinoids, the active components of the Cannabis sativa L. plant, act on the body by mimicking endogenous components – endocannabinoids – which activate special cell receptors. Cannabinoids exert various sedative effects on cancer patients. In addition, cannabinoids prevent the growth of various types of cancer cells, including glioma cells, in laboratory animals… Based on these preclinical findings, a pilot clinical study of Delta(9)-tetrahydrocannabinol (THC) in patients with recurrent glioblastoma multiforme has recently begun to be conducted.
The safe profile of tetrahydrocannabinol together with its possible containment effects on cancer cells justifies the planning of future trials with a view to assessing the potential anti-oncic effects of cannabinoids’ (34).
6. In 2005, a study entitled ‘Cannabidiol prevents the migration of human glioma cells through a mechanism independent of cannabinoid receptors’ was published in the British Journal of Pharmacology(35).
7. In 2007, a study entitled “The action of cannabinoids causes cell death by autophagy through stimulation of ER stress in human glioma cells” was published in the Journal of Clinical Investigation. The researchers of the study wrote: “Here we show that Δ(9)-tetrahydrocannabinol (THC), the main active ingredient of marijuana, causes death of human glioma cells through stimulation of autophagy. These findings describe a mechanism by which tetrahydrocannabinol can promote autophagic death in human and mouse cancer cells and provide evidence that cannabinoid administration can be an effective therapeutic strategy for human cancers” (36).
8. In 2004, a study entitled: “Cannabinoids block the biochemical pathway of vascular endothelial growth factor in gliomas” was published in the Journal of Cancer Research. The researchers of the study wrote: “Cannabinoids prevent the angiogenesis of tumors in mice, but the mechanism of their anti-angiogenic action is still unknown. Due to the fact that the biochemical pathway of the vascular endothelial growth factor (VEGF) plays an important role in the angiogenesis of tumors, here we examine, whether cannabinoids affect it.
As a first approach, cDNA analysis showed that administering cannabinoids to mice that had glioma reduced the expression of various biochemical pathways of VEGF related to genes. The use of other methods (ELISA, Western blotting, confocal microscopy) provided additional evidence that cannabinoids suppressed the vegf biochemical pathway by reducing VEGF production and activation of VEGF receptors (VEGFR-2), the most well-known VEGF receptors, in glioma cell culture in mouse gliomas.
These changes in the biochemical vegf pathway were parallel to changes in tumor size. In addition, endovascular administration of Δ(9)-tetrahydrocannabinol in two patients with glioblastoma multiforme (4th degree astrocytoma) reduced VEGF levels and the action of VEGFR-2 in tumors. Due to the fact that blocking the vegf biochemical pathway is one of the most promising approaches now available, the present findings provide an innovative pharmacological target for cannabinoid-based therapies” (37).
B. Cancer of the mouth and throat
9. In 2010, a study entitled :”Cannabinoids prevent cellular respiration in human oral cancer cells” was published in the journal Pharmacology. The researchers of the study wrote: “The main cannabinoids Delta(9)-tetrahydrocannabinol and Delta(8)-tetrahydrocannabinol are known to pose a problem in mitochondrial function and have anti-tumor properties. These observations prompted us to investigate their effects on mitochondrial consumption of O(2) in human oral cancer cells Tu183. These epithelial cells are resistant to anticancer drugs.” The conclusion of their research was: “These results show that cannabinoids are potent inhibitors of cellular respiration of Tu183 cancer cells and are toxic to these very malignant tumors” (38).
C. Breast cancer
10. In 2011 it was published in the journal Breast Cancer Research Treatment under the title “Biochemical pathways that mediate in the effects of cannabinoids in reducing the proliferation of breast cancer cells, infiltration and their metastasis”. The researchers of the study wrote: “The infiltration and metastasis of aggressive breast cancer cells are the final and fatal steps during the progression of cancer. Clinically, there are still limited therapeutic interventions available for aggressive and metastatic breast cancers. Therefore, effective, targeted and non-toxic treatments are required.
The Id-1 inhibitor has recently been shown to be the main regulator of the potential metastasis of breast cancer and other cancers. We mentioned earlier that cannabidiol (CBD), a cannabinoid with a low-toxic profile, regulated the genetic expression Id-1 in human aggressive breast cancer cells in culture… We show that cannabinoids prevent the proliferation of human breast cancer cells and their infiltration through different settings… We show that cannabinoid therapy reduces the mass of primary tumors as well as the size and number of metastases in the lungs. Our data show the effectiveness of cannabinoids in preclinical models of breast cancer. The results may lead to the development of new non-toxic components for the treatment of breast cancer metastasis” (39).
11. In 2011 a study was published in the journal PLoS One published a study showing that the ingredients of cannabis can inhibit the development and infiltration of breast cancer. The researchers of the study wrote: “Cannabinoids bind to the canabinoid receptors CB(1) and CB(2) and have been reported to have anti-oncic activity in various cancers. However, the mechanisms through which cannabinoids regulate the development of tumors are not sufficiently known. In this study we report that a synthetic non-psychotropic cannabinoid that binds specifically to cb(2) cannabinoid receptors can regulate the growth and metastasis of breast tumors by inhibiting the signaling of the CXCR4 receptor and the substitute of CXCL12. This signaling biochemical pathway has been shown to play an important role in regulating the progression and metastasis of cancer. These studies also show that CB(2) cannabinoid receptors cannabinoids can be used to develop new therapeutic strategies against breast cancer’ (40).
12. In 2006, a study entitled ‘The anti-oncic effect of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma’ (41) was published in the Journal of Pharmacology and Experimental Therapeutics.
13. In 2010, a study entitled “Cannabinoids reduce the progression of the positive to ErbB2 through inhibition of ATK” was published in the journal Molecular Cancer. The researchers of the study wrote: “ErbB2-positive breast cancer is characterized by very aggressive phenotypes and a reduced response to established therapies. Although treatments targeted to ErbB2 are designed, only a small percentage of patients respond to these treatments and most eventually relapse. The existence of this population of highly aggressive and unresponsive or recurrent cancers leads to research into new therapies.
The purpose of this treatment was to determine whether cannabinoids can be a new therapeutic tool for the treatment of breast tumors that are positive to ErbB2. Our results show that both D(9)-tetrahydrocannabinol, the most abundant and potent cannabinoid in marijuana, and JWH-133, a non-psychotropic selective CB2 receptor actor, have reduced tumor growth, the number of tumors, and the amount/severity of lung metastases in MMTV-neu mice.
Histological analyses of tumors revealed that cannabinoids prevent the proliferation of cancer cells, cause apoptosis (cell death) of cancer cells and prevent the angiogenesis of tumors. These results provide strong preclinical evidence for the use of cannabinoid-based therapies to treat ErbB2-positive breast cancer” (42).
14. In 2012, a study entitled “Cannabinoids: A New Hope for the Treatment of Breast Cancer?” was published in the journal Cancer Treatment Review. The researchers of the study wrote: “Breast cancer is a common disease that affects 1 in 10 women at some point in their lives. The most important thing is that breast cancer cannot be considered a single disease, because it is characterized by separate pathological and molecular subtypes which are treated with different treatments and have disparate clinical results. Although very effective treatments have been developed, some breast tumors are resistant to conventional treatments and a significant number of these tumors relapse.
Therefore new treatment strategies are required. Experimental evidence accumulated over the last few decades claims that cannabinoids, the active ingredients of Cannabis sativa, have anticancer activity. These components exert anti-proliferative, apoptotic (against cell death), anti-metastatic and anti-infiltrative actions on a wide range of cancer cells in culture.
In addition, tumor growth, angiogenesis and metastasis are hampered by cannabinoids in cancer-based models based on mice with xenografts. This review summarizes our current knowledge of the anti-oncic potential of cannabinoids in breast cancer, suggesting that cannabinoid-based drugs may be useful in the treatment of most subtypes of breast cancer” (43).
15. In 1998, a study entitled ‘Endogenous annandamide cannabinoid prevents the proliferation of human catcinetic breast cells’ was published in the journal PNAS. (44)
16. In 2006, a study entitled ‘Δ(9)-tetrahydrocannabinol prevents the progression of the cell cycle in human breast cancer cells by regulating Cdc2’ was published in the Journal of Cancer Research. (45)
17. In 2000, a study entitled “The suppression of neural developmental factors of Trk receptors and prolactin receptors by endocannabinoids leads to a halting of the proliferation of human breast and prostate cancer cells” was published in the journal Endocrinology (46).
D. Lung cancer
18. In 2012, it was published in the FASEB (Journal of the Federation of American Societies for Experimental Biology) under the title ‘Cannabidiol prevents the infiltration and metastasis of breast cancer cells through intracellular symphysis of the molecule-1’ (47).
19. In 2011, a study entitled ‘CB1 and CB2 kammabinoid receptors as new targets for inhibiting the growth and metastasis of small cell lung cancer cells’ was published in the journal Cancer Prevention Research(48).
20. In 2008, a study entitled ‘Δ(9)-teyrokannabinol prevents the metastasis of lung cancer cells caused by the epithelial development factor in vitro (laboratory) and their growth and metastasis in vivo (to living organisms)’ was published in the journal Oncogene.
E. Pancreatic cancer
21. In 2006, a study entitled “Cannabinoids cause apoptosis (cell death) in pancreatic tumor cells through stress of endoplasmic nucleus – related genes– was published in the Journal of Cancer Research. The researchers of the study wrote: “Pancreatic adenocarcinomas are among the most malignant forms of cancer and therefore it is of particular interest to establish new strategies to improve the prognosis of this deadly disease. This study was conducted to investigate the action of cannabinoids on pancreatic cancer. We show that cannabinoid receptors are expressed in human pancreatic tumor cells and in tumor biopsies at much higher levels than in normal pancreatic tissues.
Studies showed that administration of cannabinoids caused apoptosis (cell death), increased ceramide levels and regulated the mRNA levels of the p8 stress protein. Cannabinoids also reduced the growth of tumor cells in two animal models of pancreatic cancer. In addition, the administration of cannabinoids selectively increased apoptosis (cell death) and TRB3 expression in pancreatic tumor cells, but not in normal tissues. These findings lay the basis for a new therapeutic approach to the treatment of pancreatic cancer” (50).
F. Prostate Cancer
22. In 2003, a study entitled “Anti-proliferative and apototic effects of anandamide in human prostate cancer cells: a consequence of the regulation of receptors of epidermal developmental agents and the production of keramide” was published in the journal Prostate. The researchers of the study wrote: “Anandamide (ANA) is an endogenous lipid that acts as a substitute for cannabinoid receptors and with strong anticancer activity in various types of cancer cells. The strong anti-proliferative and cytotoxic effects of ANA on metastatic prostate cancer cells provide the basis for the design of new therapeutic agents for the effective treatment of recurrent and invasive prostate cancers” (51).
23. In 2012, a study entitled “The role of cannabinoids in prostate cancer was published in the Indian Journal of Urology. Key scientific perspectives and potential clinical applications.” The researchers of the study wrote: “Experimental evidence shows that prostate tissues have cannabinoid receptors and their stimulation contributes to anti-androgen effects. Research was done on PubMed using the terms “cannabis”, “cannavonoids”, “prostate cancer” and “cancer pain management”, highlighting the most recent publications. Prostate cancer cells have increased expression of cannabinoid receptors 1 and 2, and their stimulation contributes to reduced cell viability, increased apoptosis and decreased expression of androgen receptors and secretion of specific prostate antigens. The endocannabinoid system has recently come into the spotlight of medical research and has been considered a powerful therapeutic agent since the 1980s.
In 2005 Sarfaraz and colleagues showed increased expression of CB1 and CB2 receptors in prostate cancer cell culture compared to normal prostate cells and that the treatment of prostate cancer cells with cannabinoid acetizers CB1/CB2 WIN-55,212-2 contributes to a decrease in cell viability depending on dose and time and increased apoptosis (cell death) along with a decrease in protein expression of androgen receptors, decreased PSA expression, indicating that cannabinoids should be considered as agents in the treatment of prostate cancer.
Our conclusion is that there should be interest in conducting clinical trials that include medicinal cannabis or other cannabinoid components compared to clinical markers such as PSA with controls, particularly in men with metastatic bone cancer, who will benefit not only from the possible anti-androgenetic effects of cannabinoids, but also from the analgesia of bone pain, improving the quality of life, while reducing the consumption of narcotic drugs and non-dependence on opioids.”
The researchers also refer to cancer pain management with cannabinoids: “CB1 cannabinoid receptors are found mainly in the central nervous system and in less abundance in some peripheral tissues. At a regional level, they are found in the adrenal glands, adipose tissues, heart, liver, lungs, prostate, uterus, ovaries, testicles, bone marrow, thymus, tonsils and presynaptic nerve endings. Most important for the purposes of this inspection, they are located at the central and peripheral levels of the biochemical pathways of pain. The distribution of cannabinoid receptors provides an anatomical explanation for the analgesic effects of cannabinoids. Δ(9)-tetrahydrocannabinol is the ingredient with the greatest psychostimulatory power of natural cannabinoids and has the greatest analgesic effect.
Cannabidiol, another large component of the Cannabis sativa plant, has the same therapeutic effects as tetrahydrocannabinol (analgesics, anti-inflammatory and others), but with a different pharmacological profile. The effect of cannabinoids has also been studied clinically on pain cancer. Initial studies determined the moderate effect of 20mg of oral Δ(9)-tetrahydrocannabinol equivalent to 120mg of codeine (alkaloid produced by opium)’ (52).
24. In 2014, a study entitled ‘Non-THC cannabinoids prevent the development of prostate carcinoma in vitro and in vivo: apoptotic effects and underlying mechanisms’ was published in the British Journal of Pharmacology(53).
G. Bowel Cancer
25. In 2012, a study entitled “The chemo-preventive effect of non-psychotropic phytocannabinoid cannabidiol on experimental bowel cancer” was published in the Journal of Molecular Medicine. The researchers of the study wrote: “Cannabidiol, a safe and non-psychotropic component of Cannabis sativa has pharmacological actions (antioxidant and anti-inflammatory bowel) and mechanisms (inhibition of enzymatic decomposition of endocannabinoids) potentially beneficial for intestinal carcinogenesis. The conclusion is that cannabidiol exerts a chemo-preventive effect in vivo (on living organisms) and reduces cell proliferation through multiple mechanisms” (54).
26. In 2009, a study entitled “Cannabinoids in intestinal inflammation and cancer” was published in the journal Pharmacology Research. The study’s researchers wrote: “Emerging evidence suggests that cannabinoids have beneficial effects on intestinal inflammation and cancer. Adaptive changes in the endocannabinoid system have been observed in bowel biopsies from patients with inflammatory intestinal diseases and bowel cancer. Studies in epithelial cells have shown that cannabinoids exert anti-proliferative, anti-metastatic and apoptotic effects as well as reduced release of cytokine and promote wound treatment. In living organisms, cannabinoids – through direct or indirect activation of receptors CB(1) and/or CB(2) – exert protective effects on well-established models of intestinal inflammation and bowel cancer. Pharmacological elevation of endocannabinoid levels can be a promising strategy for the treatment of intestinal inflammation and bowel cancer” (55).
27. In 2005, a study entitled ‘Endogenous cannabinoid, anandamide, causes cell death in bowel carcinoma cells: a possible role in cyclo-oxygenase 2’ was published in the journal Gut.
28. In 2008, a study by the University of Texas, M.D. Anderson Cancer Center was published entitled “The closure of cannabinoid receptors causes the development of bowel tumors”. Let’s see what the university’s study says: “New preclinical research shows that the CB1 receptor of the surface of cannabinoid cells plays a sedative role for tumors in human bowel cancer, scientists said in the August edition of the journal Cancer Research. CB1 is well recognized for relieving pain and nausea, improving mood and stimulating appetite. It now serves as a new path to the prevention and treatment of cancer.
“We have found that the expression of CB1 is lost in most cancers, and when this happens, a protein that promotes cancer is free to prevent cell death,” said doctor Raymond DuBois, dean and vice president of the University of Texas M.D. Anderson Cancer Center. DuBois and colleagues from the Vanderbilt-Ingram Cancer Center also show that the expression of CB1 can be restored with an existing drug, decitabine. They found that mice that tended to develop cancer, and which also had functional CB1 receptors, developed fewer and smaller cancers when treated with a drug that mimics a cannabinoid receptor substitute.
Ligands or substitutes are molecules that work by binding to special receptors. Agonists are synthetic molecules that mimic the action of a natural molecule. “The potential application of cannabinoids as anti-oncic drugs is an exciting prospect because synthetic substances that mimic the action of natural cannabinoids are now being evaluated to treat the side effects of chemotherapy and radiation therapy,” DuBois said. The reintroduction of CB1 and treatment with synthetic substances mimicking the action of natural cannabinoids could provide a new approach to the treatment or prevention of bowel cancer” (57).
The. Ovarian cancer
29. In 2006, a study entitled “Cannabinoid receptors as a target for the treatment of ovarian cancer” was published in the American Association of Cancer Research. The researchers of the study wrote: “Ovarian cancer presents one of the main causes of cancer-related deaths in women and is the most common gynecological malignancy. Ovarian cancer has a high mortality rate, with a total five-year survival rate of less than 30%. At the moment, there are insufficient treatment options for the treatment of ovarian cancer and therefore new approaches need to be developed to treat this disease.
Cannabinoids, the active ingredients of Cannabis sativa and their derivatives have received significant attention in recent years due to their different pharmacological actions, such as inhibition of cell growth and tumor regression.” The researchers analyze the data on the therapeutic effect of cannabis on ovarian cancer and stress the need for a new therapeutic approach to ovarian cancer with cannabinoids (58).
I. Blood Cancer
30. In 2002, a study entitled ‘Targeting cannabinoid receptors as a new treatment for the treatment of malignant lymphoblastic disease’ was published in the journal Blood (59).
31. In 2006, a study titled “Delta(9)-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by a shift of Bad in mitochodria was published in the journal Molecular Cancer Research. The researchers of the study wrote: “Plant cannabinoids, including Delta(9)-tetrahydrocannabinol, cause apoptosis (cell death) in leukemic cells, although the exact mechanism remains unclear.” The researchers of this study examine the mechanisms of the anticancer activity of cannabinoids against leukemia (60).
32. In 2008, a study entitled ‘Expression of type 1 and 2 cannabinoid receptors in non-Hodgkin’s lymphoma: Inhibition of growth through receptor activation” was published in the International Journal of Cancer.” (61)
I. Skin cancer
33. In 2003, a study entitled ‘Inhibiting the growth of skin tumors and angiogenesis by activating cannabinoid receptors’ (62) was published in the Journal of Clinical Investigation.
K. Liver cancer
34. In 2011, a study entitled “The anti-oncic effect of cannabinoids in hepatocellular carcinoma: the role of AMPK-dependent activation in autophagy” was published in the journal Cell Death and Differentiation. The researchers of the study wrote: “Hepatocellular carcinoma is the third cause of cancer-related death worldwide. When these tumors are in advanced stages, few treatment options are available. Therefore, it is necessary to make research into new treatments to combat the disease. In this study, we investigated the effects of cannabinoids on the development of hepatocellular carcinoma.
We found that D(9)-tetrahydrocannabinol, the main component of Cannabis sativa, and JWH-015 (a substance that mimics cannabinoid receptors) reduced the viability of human liver cells HepG2 (human hepatocellular carcinoma cells) and HuH-7 (hepatocellular carcinoma cells), an effect due to the stimulation of CB receptors(2). Cannavonoids were able to inhibit the growth of tumors. Our findings may contribute to new therapeutic strategies for the treatment of hepatocellular carcinoma” (63).
L. Bladder Cancer
35. In 2013, a study was published in a publication of the American Urological Association showing that cannabis reduces the risk of bladder cancer. This news story was published on May 10, 2013 by Medscape under the title “Marijuana can reduce the risk of bladder cancer.” Let’s see what the publication says:
“Smoking marijuana can reduce a smoker’s risk of bladder cancer, a new study shows. Retrospectively analyzing a large patient database, researchers at Kaiser Permanente in California found that patients who reported cannabis use were 45% less likely to be diagnosed with bladder cancer than patients who did not smoke at all. “It’s very impressive because bladder cancer is hard to treat,” said Anil Thomas, a urologist at southern California Permanente’s medical team.
Dr. Thomas presented the study at the 2013 annual scientific meeting of the American Association of Urology. “We know that smoking tobacco (cigarette, pipe) is the most well-founded risk for bladder cancer,” said Dr. Thomas. “But today there are no epidemiological studies that accurately characterize the link between cannabis use and bladder cancer.”
To fill the gap, Dr. Thomas and colleagues analyzed an inspection of 82,050 men by Northern and Southern California Kaiser Permanente, a health conservation organization, conducted in 2002 and 2003. During the upcoming 11 years, most patients who reported not using cannabis than those who reported using them developed tumors in the bladder. The difference was statistically significant. However, patients who smoked only tobacco (cigarettes or pipes) had an increased risk of bladder cancer, and those who smoked both tobacco and marijuana had about the same risk as those who smoked neither. This may explain why previous studies had not revealed the protective effect of marijuana, Dr. Thomas said. To see results, it is necessary to distinguish marijuana smokers from those who do not smoke tobacco” (64).
The results are impressive. This study shows that cannabis protects against bladder cancer (and certainly from other cancers), while tobacco (cigarette, etc.) causes bladder cancer (and many other cancers). And yet cigarettes are allowed, while cannabis is banned!
Cannabis can be a cancer drug, and it helps in many other ailments much more effectively and safely than prescription chemicals. The fact that someone cannot go to his doctor or a Greek hospital and legally use cannabis to be cured of cancer (or any other condition that cannabis helps, such as epilepsy), I consider it criminal. In this way, some cunning people can illegally sell hemp oil (which may not be authentic hemp oil) and treasure at the expense of the consumer’s health.
Some pharmaceutical companies have manufactured synthetic cannabinoids, but these are not as safe as the plant’s natural cannabinoids, and have side effects. The free medicinal use of cannabis is a threat to pharmaceutical companies, because the pharmaceutical use of this plant will make most of the medicinal products in the trade be thrown in the bin. The non-free medicinal use of cannabis is a crime for humanity!
(Note: This chapter on cannabis is for informational purposes only; we do not approve of the use of cannabis for any purpose other than for medical use. Consult your doctor if you would like to use medicinal cannabis to treat your condition).
Two of Marios Dimopoulos’ books are “Prevent Prostate and Breast Cancer – All Natural Therapies” and “Natural Methods of Cancer Treatment”
Source: Alternative Action